Industry news that matters to you.  Learn more

Asterand Bioscience and MolecularMD Announce a Partnership to Accelerate Targeted Therapeutic Biomarker Validation, Optimization, Development and Commercialization

Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today a partnership with MolecularMD to combine MolecularMD’s expertise as a provider of molecular diagnostics products and services with Asterand Bio’s drug target and candidate validation capabilities. MolecularMD is a molecular diagnostics company that develops custom clinical trial assays as well as companion diagnostic products, supporting clinical trial services and commercialization of targeted cancer therapies. The partnership creates an end-to-end workflow for biopharma clients and strengthens the companies’ current offerings in assay development & validation, while creating a global footprint for the efficient delivery of clinical trial sample analyses.

Resilience and PsychoGenics Announce a Drug Discovery Partnership

Resilience Therapeutics, Inc. (Resilience) and PGI Drug Discovery LLC (PsychoGenics), recently announced that they have entered into a partnership to discover and optimize novel treatments for Post-Traumatic Stress Disorder (PTSD) and related conditions.

World Fusion and Lumenogix Announce Global Strategic Partnership

World Fusion Co., LTD and Lumenogix Inc. recently announced a strategic partnership to provide a complete solution for the pharmaceutical industry that integrates the World Fusion Life Sciences Knowledge Bank (LSKB) for accelerating drug discovery with the Lumenogix Bioinformatics-in-a-Box™ for analyzing Next Generation Sequencing (NGS) data.

20/20 HealthCare Partners Collaborates with Roche to Source and Advance BioTech Innovations

20/20 HealthCare Partners LLC (20/20 HCP), a global investment group focused on early stage medical technology and life science innovation, recently announcd an agreement with Roche, in which they will source and identify novel treatments and/or technologies in the biotech arena. These areas include oncology/immuno-oncology, neurology, infectious diseases, inflammation and ophthalmology.

Strand Genomics Inc. And BioHealth Innovation, Inc. Partner To Expand Strand Centers For Genomics & Personalized Medicine In The U.S.

Strand Genomics Inc. (Strand) and BioHealth Innovation, Inc. (BHI) recently announced a strategic partnership designed to expand the Strand Centers for Genomics & Personalized Medicine into the U.S. This effort is intended to help revolutionize access to genomic interpretation services in cardiovascular disease, oncology, rare diseases, and many other indications. Strand Genomics is a wholly owned subsidiary of Strand Life Sciences, a Bangalore, India-based bioinformatics, clinical genomics, and diagnostics company.